Fully Automated HTS Platform for Screening Diverse Targets

High-throughput screening (HTS) remains a foundational technology in early drug discovery, responsible for identifying approximately one-third of today’s clinical candidates. As therapeutic targets become more complex, the demand for HTS platforms that combine high capacity with scientific flexibility continues to grow.

At SLAS 2026, WuXi Biology and Testing presented a poster highlighting our fully automated HTS platform, built within a biosafety level 2 (BSL-2) laboratory, enabling safe and efficient processing of immortalized cell lines, primary cells, and clinical samples. The system integrates robotic liquid handling, plate storage/incubation, and multimodal detection, supporting both endpoint and kinetic assays in 384- and 1536-well formats.